A.R.T. Advisors LLC acquired a new position in Sarepta Therapeutics Inc (NASDAQ:SRPT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 8,700 shares of the biotechnology company’s stock, valued at approximately $1,322,000.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. US Bancorp DE lifted its holdings in Sarepta Therapeutics by 16.1% in the 2nd quarter. US Bancorp DE now owns 1,193 shares of the biotechnology company’s stock worth $181,000 after purchasing an additional 165 shares in the last quarter. Virtus ETF Advisers LLC bought a new position in Sarepta Therapeutics in the 2nd quarter valued at $1,029,000. ETRADE Capital Management LLC grew its position in Sarepta Therapeutics by 5.2% in the 2nd quarter. ETRADE Capital Management LLC now owns 3,107 shares of the biotechnology company’s stock valued at $472,000 after acquiring an additional 153 shares during the last quarter. United Capital Financial Advisers LLC grew its position in Sarepta Therapeutics by 4.3% in the 2nd quarter. United Capital Financial Advisers LLC now owns 15,623 shares of the biotechnology company’s stock valued at $2,374,000 after acquiring an additional 643 shares during the last quarter. Finally, BSW Wealth Partners bought a new position in Sarepta Therapeutics in the 2nd quarter valued at $52,000. Institutional investors own 95.09% of the company’s stock.
In other news, Director Richard Barry purchased 1,300 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average cost of $122.50 per share, for a total transaction of $159,250.00. Following the completion of the purchase, the director now owns 3,173,365 shares of the company’s stock, valued at $388,737,212.50. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael W. Bonney purchased 2,000 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were acquired at an average cost of $86.74 per share, for a total transaction of $173,480.00. Following the acquisition, the director now owns 7,051 shares of the company’s stock, valued at approximately $611,603.74. The disclosure for this purchase can be found here. Insiders acquired 35,752 shares of company stock worth $3,940,114 over the last three months. 6.60% of the stock is currently owned by corporate insiders.
NASDAQ:SRPT traded up $0.32 during trading hours on Friday, reaching $83.48. 663,358 shares of the company traded hands, compared to its average volume of 1,751,597. Sarepta Therapeutics Inc has a 1-year low of $72.05 and a 1-year high of $158.80. The stock has a market cap of $6.01 billion, a P/E ratio of -15.29 and a beta of 2.12. The firm’s 50-day moving average is $85.07 and its 200-day moving average is $117.97. The company has a debt-to-equity ratio of 0.44, a current ratio of 8.81 and a quick ratio of 7.84.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($3.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.08) by ($2.66). Sarepta Therapeutics had a negative return on equity of 55.37% and a negative net margin of 165.52%. The business had revenue of $94.67 million for the quarter, compared to analysts’ expectations of $91.05 million. During the same period in the prior year, the company earned ($1.67) EPS. The company’s revenue for the quarter was up 28.8% compared to the same quarter last year. As a group, research analysts predict that Sarepta Therapeutics Inc will post -4.94 earnings per share for the current year.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Further Reading: Basic Economics
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.